Company Focus
Biogen
Latest Biogen News
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Biogen
Biotechnology
Swiss family-owned protein specialist Octapharma has appointed pharmaceutical industry veteran Kelly Hearn as vice president of commercial development and marketing of its American company, Octapharma USA.
Ms Hearn will take immediate leadership 20 May 2024
Biotechnology
Inaugurated last Friday (May 17), the Pasteur Fiocruz Center on Immunology and Immunotherapy, located at Fiocruz Ceará, brings together scientists from the France-based Institut Pasteur and Brazil’s Fiocruz, two members of the Pasteur Network, to develop an integrative approach towards immunotherapies applied to both infectious and non-communicable diseases. 20 May 2024
Biotechnology
On the deal-making front last week, US rare disease focused biotech Fulcrum Therapeutics out-licensed ex-USA rights for its muscular dystrophy candidate losmapimod to French pharma major Sanofi for a modest $80 million upfront but with a further $975 million on the line. Research developments included US biotech Cytokinetics releasing Phase III data on its investigational cardiomyopathy drug aficamten, while US biotech major Biogen pulled the plug on two antisense oligonucleotide programs – BIIB105 and BIIB121 – being developed with Ionis Pharmaceutical. Also of note, Blackstone Life Sciences un-stealthed Uniquity Bio with a US Food and Drug Administration (FDA)-accepted investigational new drug (IND) for the monoclonal antibody solrikitug and $300 million financing. 19 May 2024
Expert View
In an Expert View column, Bruce Leuchter, chief executive of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company, outlines the importance of increased investment in research and development and innovative business models, to bring more therapies for neurological disorders to patients. 17 May 2024
Pharmaceutical
Boston, USA-based start-up Monte Rosa Therapeutics intends to raise around $100 million through a public share offering. 17 May 2024
Biotechnology
American biopharma company Biogen is to pull the plug on two antisense oligonucleotide (ASO) programs. 17 May 2024
Pharmaceutical
Jo Latimer, head of neurosciences and mental health at the UK’s Medical Research Council (MRC), has been appointed chief scientific officer at a charity performing research in the dementia field.
Beginning mid-August, Dr Latimer will take up the role with the UK Dementia Research Institute (UK DRI), a multimillion-pound investment which is principally funded by MRC. 16 May 2024
Biotechnology
Blackstone has announced the launch of the Blackstone Life Sciences portfolio company Uniquity Bio, a clinical-stage drug developer on immunology and inflammation. 16 May 2024
Pharmaceutical
Shares in Merck KGaA rose by around 5% in Wednesday’s trading after the Germany-based company presented its first quarter financial results and latest forecast for 2024. 15 May 2024
Pharmaceutical
A US Food and Drug Administration (FDA) panel will consider Lykos Therapeutics’ filing for midomafetamine capsules (MDMA) as a therapy-assisted treatment for post-traumatic stress disorder (PTSD) in early June. 15 May 2024
Latest In Brief for Biogen
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Latest Relevant Ones To Watch News
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
12 November 2024
5 November 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze